For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/management-approaches-for-eoe-9991

Summary
The American College of Gastroenterology has published the first new guidelines for the treatment of eosinophilic esophagitis (EoE) since 2013. In this CME/CE podcast, Drs. Paul Feuerstadt and Brooks Cash discuss these latest recommendations, reviewing the role of proton pump inhibitors, topical steroids, diet elimination, a biologic, and esophageal dilation in the management of this increasingly recognized condition.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Assess the efficacy and safety profile of approved agents for EoE, with a focus on swallowed corticosteroids, in the management of EoE
• Apply evidence-based guidelines to optimize treatment outcomes and improve the quality of life for patients with EoE

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.